AGILON HEALTH INC (AGL) Fundamental Analysis & Valuation

NYSE:AGL • US00857U1079

Current stock price

0.437 USD
0 (-0.68%)
Last:

This AGL fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

0

1. AGL Profitability Analysis

1.1 Basic Checks

  • In the past year AGL has reported negative net income.
  • In the past year AGL has reported a negative cash flow from operations.
  • AGL had negative earnings in each of the past 5 years.
  • AGL had a negative operating cash flow in each of the past 5 years.
AGL Yearly Net Income VS EBIT VS OCF VS FCFAGL Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 2025 -100M -200M -300M -400M

1.2 Ratios

  • Looking at the Return On Assets, with a value of -30.78%, AGL is doing worse than 83.00% of the companies in the same industry.
  • Looking at the Return On Equity, with a value of -308.79%, AGL is doing worse than 80.00% of the companies in the same industry.
Industry RankSector Rank
ROA -30.78%
ROE -308.79%
ROIC N/A
ROA(3y)-20.29%
ROA(5y)-18.56%
ROE(3y)-134.57%
ROE(5y)-90.24%
ROIC(3y)N/A
ROIC(5y)N/A
AGL Yearly ROA, ROE, ROICAGL Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 2025 -100 -200 -300 -400 -500

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for AGL so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
AGL Yearly Profit, Operating, Gross MarginsAGL Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 2025 0 10 -10 -20 -30

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

2

2. AGL Health Analysis

2.1 Basic Checks

  • AGL does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, AGL has more shares outstanding
  • The number of shares outstanding for AGL has been increased compared to 5 years ago.
  • AGL has a worse debt/assets ratio than last year.
AGL Yearly Shares OutstandingAGL Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M 400M
AGL Yearly Total Debt VS Total AssetsAGL Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 2025 500M 1B 1.5B

2.2 Solvency

  • Based on the Altman-Z score of 1.49, we must say that AGL is in the distress zone and has some risk of bankruptcy.
  • AGL's Altman-Z score of 1.49 is in line compared to the rest of the industry. AGL outperforms 41.00% of its industry peers.
  • AGL has a Debt/Equity ratio of 0.12. This is a healthy value indicating a solid balance between debt and equity.
  • AGL has a Debt to Equity ratio of 0.12. This is in the better half of the industry: AGL outperforms 73.00% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.12
Debt/FCF N/A
Altman-Z 1.49
ROIC/WACCN/A
WACC9.79%
AGL Yearly LT Debt VS Equity VS FCFAGL Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 2025 0 200M 400M 600M 800M 1B

2.3 Liquidity

  • AGL has a Current Ratio of 1.02. This is a normal value and indicates that AGL is financially healthy and should not expect problems in meeting its short term obligations.
  • AGL's Current ratio of 1.02 is on the low side compared to the rest of the industry. AGL is outperformed by 71.00% of its industry peers.
  • AGL has a Quick Ratio of 1.02. This is a normal value and indicates that AGL is financially healthy and should not expect problems in meeting its short term obligations.
  • AGL has a Quick ratio of 1.02. This is in the lower half of the industry: AGL underperforms 63.00% of its industry peers.
Industry RankSector Rank
Current Ratio 1.02
Quick Ratio 1.02
AGL Yearly Current Assets VS Current LiabilitesAGL Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 2025 500M 1B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. AGL Growth Analysis

3.1 Past

  • The earnings per share for AGL have decreased strongly by -50.79% in the last year.
  • AGL shows a decrease in Revenue. In the last year, the revenue decreased by -2.11%.
  • Measured over the past years, AGL shows a very strong growth in Revenue. The Revenue has been growing by 37.25% on average per year.
EPS 1Y (TTM)-50.79%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-76.92%
Revenue 1Y (TTM)-2.11%
Revenue growth 3Y29.87%
Revenue growth 5Y37.25%
Sales Q2Q%3.09%

3.2 Future

  • The Earnings Per Share is expected to grow by 23.49% on average over the next years. This is a very strong growth
  • AGL is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 5.84% yearly.
EPS Next Y63.09%
EPS Next 2Y32.8%
EPS Next 3Y23.49%
EPS Next 5YN/A
Revenue Next Year-6.24%
Revenue Next 2Y-0.77%
Revenue Next 3Y3.75%
Revenue Next 5Y5.84%

3.3 Evolution

  • The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
AGL Yearly Revenue VS EstimatesAGL Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2B 4B 6B
AGL Yearly EPS VS EstimatesAGL Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 -0.2 -0.4 -0.6 -0.8 -1

More info and screens

Find the best growth stocksShow best growing peers

1

4. AGL Valuation Analysis

4.1 Price/Earnings Ratio

  • AGL reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year AGL is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
AGL Price Earnings VS Forward Price EarningsAGL Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40 50

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
AGL Per share dataAGL EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10

4.3 Compensation for Growth

  • A more expensive valuation may be justified as AGL's earnings are expected to grow with 23.49% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y32.8%
EPS Next 3Y23.49%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. AGL Dividend Analysis

5.1 Amount

  • AGL does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

AGL Fundamentals: All Metrics, Ratios and Statistics

AGILON HEALTH INC

NYSE:AGL (3/24/2026, 5:05:00 PM)

0.437

0 (-0.68%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)02-25
Earnings (Next)05-04
Inst Owners65.45%
Inst Owner Change-1.16%
Ins Owners1.57%
Ins Owner Change9.85%
Market Cap181.30M
Revenue(TTM)5.93B
Net Income(TTM)-391.35M
Analysts55
Price Target1.01 (131.12%)
Short Float %7.98%
Short Ratio3.4
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-69.2%
Min EPS beat(2)-69.54%
Max EPS beat(2)-68.86%
EPS beat(4)1
Avg EPS beat(4)42.36%
Min EPS beat(4)-114.66%
Max EPS beat(4)422.51%
EPS beat(8)3
Avg EPS beat(8)2.31%
EPS beat(12)4
Avg EPS beat(12)-2.5%
EPS beat(16)4
Avg EPS beat(16)-25.3%
Revenue beat(2)1
Avg Revenue beat(2)3.07%
Min Revenue beat(2)-0.19%
Max Revenue beat(2)6.33%
Revenue beat(4)2
Avg Revenue beat(4)0.23%
Min Revenue beat(4)-6.13%
Max Revenue beat(4)6.33%
Revenue beat(8)2
Avg Revenue beat(8)-1.09%
Revenue beat(12)6
Avg Revenue beat(12)0.54%
Revenue beat(16)10
Avg Revenue beat(16)1.1%
PT rev (1m)0%
PT rev (3m)-2.08%
EPS NQ rev (1m)294.31%
EPS NQ rev (3m)300.35%
EPS NY rev (1m)17.45%
EPS NY rev (3m)16.91%
Revenue NQ rev (1m)-12.11%
Revenue NQ rev (3m)-12.6%
Revenue NY rev (1m)-8.19%
Revenue NY rev (3m)-9.28%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.03
P/FCF N/A
P/OCF N/A
P/B 1.43
P/tB 2.97
EV/EBITDA N/A
EPS(TTM)-0.95
EYN/A
EPS(NY)-0.35
Fwd EYN/A
FCF(TTM)-0.36
FCFYN/A
OCF(TTM)-0.25
OCFYN/A
SpS14.3
BVpS0.31
TBVpS0.15
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -30.78%
ROE -308.79%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-20.29%
ROA(5y)-18.56%
ROE(3y)-134.57%
ROE(5y)-90.24%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover4.67
Health
Industry RankSector Rank
Debt/Equity 0.12
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 150.76%
Cap/Sales 0.73%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.02
Quick Ratio 1.02
Altman-Z 1.49
F-Score4
WACC9.79%
ROIC/WACCN/A
Cap/Depr(3y)157.46%
Cap/Depr(5y)160.22%
Cap/Sales(3y)0.71%
Cap/Sales(5y)0.81%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-50.79%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-76.92%
EPS Next Y63.09%
EPS Next 2Y32.8%
EPS Next 3Y23.49%
EPS Next 5YN/A
Revenue 1Y (TTM)-2.11%
Revenue growth 3Y29.87%
Revenue growth 5Y37.25%
Sales Q2Q%3.09%
Revenue Next Year-6.24%
Revenue Next 2Y-0.77%
Revenue Next 3Y3.75%
Revenue Next 5Y5.84%
EBIT growth 1Y-48.02%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year76.8%
EBIT Next 3Y28.42%
EBIT Next 5Y18.78%
FCF growth 1Y-50.28%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-83.05%
OCF growth 3YN/A
OCF growth 5YN/A

AGILON HEALTH INC / AGL Fundamental Analysis FAQ

What is the ChartMill fundamental rating of AGILON HEALTH INC (AGL) stock?

ChartMill assigns a fundamental rating of 2 / 10 to AGL.


Can you provide the valuation status for AGILON HEALTH INC?

ChartMill assigns a valuation rating of 1 / 10 to AGILON HEALTH INC (AGL). This can be considered as Overvalued.


Can you provide the profitability details for AGILON HEALTH INC?

AGILON HEALTH INC (AGL) has a profitability rating of 0 / 10.


What is the earnings growth outlook for AGILON HEALTH INC?

The Earnings per Share (EPS) of AGILON HEALTH INC (AGL) is expected to grow by 63.09% in the next year.